Preference-based Assessment
With the growth in the use of health economic evaluation to inform healthcare resource allocation decisions, the challenges in applying standard methods to child health have become apparent. This paper presents and discusses existing and novel options for deriving utilities for paediatric health states for use in CUAs. (Source: AdisOnline.com, Ungar, Wendy J.)
Health Utilities Inc (HUInc) specializes in preference-based (utility) measures of health-related quality of life for use in describing treatment processes and outcomes in clinical studies; economic evaluations of health care programs; the measurement and monitoring of population health.
Authors advocate $US 50,000 per QALY benchmark for determining value for money should be updated, and must vary across payers, populations and even procedures. (Source: PharmacoEconomics: 1 March 2010 - Volume 28 - Issue 3 - pp 175-184)
Over recent years there has been renewed interest in cost-benefit analysis (CBA) in health care but the 'hypothetical bias' concern (i.e. the belief that WTP values overstate real preferences) is a remaining anxiety. This paper reports new empirical data comparing hypothetical and real preferences in a health care context, using the clinical setting of patient self-management (PSM) of anticoagulation (warfarin) therapy. (Source: Health Economics, Dec. 2010)
.
Presentation at ISPOR Europe, Nov. 2011, by Dominique Dubois, MD, FFPM, FBCPM, Managing Director, Outcomes Research, Patient Value Solutions, Huldenberg, Belgium
The health reform bill that was passed in the United States last year contained a provision to set up an entity called the Patient Centered Outcomes Research Institute, or PCORI.
An interview with Dr. Berwick, a Harvard pediatrician and president for the Institute for Healthcare Improvement, about mandatory shared (between physician and patient) decision-making. Very interesting conundrum.
Link to the ISPOR Working Group. Goal is to increase the appropriate use of methods for measurement of patient preferences and values in outcomes research and the use of this information in health care technology assessment.
Report of the network.
This article provides a discussion of QALYs and the use of Condition Specific Measures (preference-based).
ISPOR QALY Consensus Development Workshop Building a Pragmatic Road: An ISPOR Development Workshop on Moving the QALY Forward
Presentation at ISPOR Europe, Nov. 2011, by Mark Nuijten PhD, MD, MBA, Consultant, Health Economics, Ars Accessus Medica, Amsterdam (Jisp), The Netherlands
Presentation at ISPOR Europe, Nov. 2011, by Gerry Oster, PhD, Vice President, Policy Analysis Inc. (PAI), Brookline, MA, USA
This blog post discusses how health care decisions are made given consideration for testing results (especially false negatives) by insurance companies and government policy. (Source: Meep, POWIP, Nov 22, 2009)
Presentation at ISPOR Europe, Nov. 2011 by Louise Longworth, PhD, Reader in Health Economics, Health Economics Research Group, Brunel University, Uxbridge, UK
Presentation at ISPOR Europe, Nov. 2011 by Brendan Mulhern, Msc, Researcher, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
The objective of this paper is to examine how well the QALY captures the health gains generated by cancer treatments, with particular focus on the methods for constructing QALYs preferred by the UK National Institute for Health and Clinical Excellence (NICE).
The quality-adjusted life-year (QALY) has come under fire lately. In the United States, health reform legislation prohibited use of cost-per-QALY thresholds. 1 The United Kingdom has proposed that the National Institute for Health and Clinical Excellence (NICE), which has influenced reimbursement through cost-per-QALY ratios, will not in the future use such information to make yes or no recommendations; instead NICE's cost-effectiveness assessments would provide an input into price negotiations for technologies. (Source: JAMA, Peter J. Neumann)
Fundamental overview of QALY and ICER (Source: Minyanville, Author: David Miller)
For many treatments, we know neither the true probability of success nor how to explain it clearly to a sick and worried patient. The Affordable Care Act has begun a dialogue about how to generate this probability evidence, and put into motion a number of initiatives to help fill the present knowledge gap. The Patient-Centered Outcomes Research Institute will do vital work to generate the comparative effectiveness studies that inform doctors of a treatment's risks.
